Lack of Widespread BBB Disruption in Alzheimer's Disease Models: Focus on Therapeutic Antibodies

Neuron

Volumn 88, Issue 2, 2015, Pages 289-297

  Bien Ly, Nga ^a   Boswell, C Andrew ^a   Jeet, Surinder ^a   Beach, Thomas G ^b   Hoyte, Kwame ^a   Luk, Wilman ^a   Shihadeh, Vera ^a   Ulufatu, Sheila ^a   Foreman, Oded ^a   Lu, Yanmei ^a   DeVoss, Jason ^a   van der Brug, Marcel ^a   Watts, Ryan J ^a  

^a GENENTECH INC   (United States)

^b SUN HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA SECRETASE 1; TRANSFERRIN RECEPTOR; ANTIBODY; EDNSFV ANTI-TRANSFERRIN RECEPTOR; HYBRID PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN INFARCTION SIZE; BRAIN SIZE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOLECULAR WEIGHT; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TRANSGENIC MOUSE; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; FEMALE; KNOCKOUT MOUSE; MALE; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; ANIMALS; ANTIBODIES; BLOOD-BRAIN BARRIER; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES;

EID: 84944881561     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2015.09.036     Document Type: Article

References (34)

1. Alata W., Ye Y., St-Amour I., Vandal M., Calon F. Human apolipoprotein E ε4 expression impairs cerebral vascularization and blood-brain barrier function in mice. J. Cereb. Blood Flow Metab. 2015, 35:86-94.
2. Attems J. Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms. Acta Neuropathol. 2005, 110:345-359.
3. Atwal J.K., Chen Y., Chiu C., Mortensen D.L., Meilandt W.J., Liu Y., Heise C.E., Hoyte K., Luk W., Lu Y., et al. A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo. Sci. Transl. Med. 2011, 3:84ra43.
4. Bateman G.A., Levi C.R., Schofield P., Wang Y., Lovett E.C. Quantitative measurement of cerebral haemodynamics in early vascular dementia and Alzheimer's disease. J. Clin. Neurosci. 2006, 13:563-568.
5. Beach T.G., Adler C.H., Sue L.I., Serrano G., Shill H.A., Walker D.G., Lue L., Roher A.E., Dugger B.N., Maarouf C., et al. Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program. Neuropathology 2015, 35:354-389.
6. Bell R.D., Winkler E.A., Singh I., Sagare A.P., Deane R., Wu Z., Holtzman D.M., Betsholtz C., Armulik A., Sallstrom J., et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 2012, 485:512-516.
7. Bennett J., Basivireddy J., Kollar A., Biron K.E., Reickmann P., Jefferies W.A., McQuaid S. Blood-brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model EAE. J. Neuroimmunol. 2010, 229:180-191.
8. Bien-Ly N., Yu Y.J., Bumbaca D., Elstrott J., Boswell C.A., Zhang Y., Luk W., Lu Y., Dennis M.S., Weimer R.M., et al. Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants. J. Exp. Med. 2014, 211:233-244.
9. Blair L.J., Frauen H.D., Zhang B., Nordhues B.A., Bijan S., Lin Y.C., Zamudio F., Hernandez L.D., Sabbagh J.J., Selenica M.L., Dickey C.A. Tau depletion prevents progressive blood-brain barrier damage in a mouse model of tauopathy. Acta Neuropathol. Commun. 2015, 3:8.
10. Boswell C.A., Bumbaca D., Fielder P.J., Khawli L.A. Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations. AAPS J. 2012, 14:612-618.
11. Bridges L.R., Andoh J., Lawrence A.J., Khoong C.H., Poon W.W., Esiri M.M., Markus H.S., Hainsworth A.H. Blood-brain barrier dysfunction and cerebral small vessel disease (arteriolosclerosis) in brains of older people. J. Neuropathol. Exp. Neurol. 2014, 73:1026-1033.
12. Couch J.A., Yu Y.J., Zhang Y., Tarrant J.M., Fuji R.N., Meilandt W.J., Solanoy H., Tong R.K., Hoyte K., Luk W., et al. Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Sci. Transl. Med. 2013, 5:183ra57. 1-12.
13. De Reuck J.L. The significance of small cerebral bleeds in neurodegenerative dementia syndromes. Aging Dis. 2012, 3:307-312.
14. Del Ser T., Hachinski V., Merskey H., Munoz D.G. Alzheimer's disease with and without cerebral infarcts. J. Neurol. Sci. 2005, 231:3-11.
15. Do T.M., Alata W., Dodacki A., Traversy M.T., Chacun H., Pradier L., Scherrmann J.M., Farinotti R., Calon F., Bourasset F. Altered cerebral vascular volumes and solute transport at the blood-brain barriers of two transgenic mouse models of Alzheimer's disease. Neuropharmacology 2014, 81:311-317.
16. Erickson M.A., Banks W.A. Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease. J. Cereb. Blood Flow Metab. 2013, 33:1500-1513.
17. Farrall A.J., Wardlaw J.M. Blood-brain barrier: ageing and microvascular disease--systematic review and meta-analysis. Neurobiol. Aging 2009, 30:337-352.
18. Grueninger F., Bohrmann B., Czech C., Ballard T.M., Frey J.R., Weidensteiner C., von Kienlin M., Ozmen L. Phosphorylation of Tau at S422 is enhanced by Abeta in TauPS2APP triple transgenic mice. Neurobiol. Dis. 2010, 37:294-306.
19. Hafezi-Moghadam A., Thomas K.L., Wagner D.D. ApoE deficiency leads to a progressive age-dependent blood-brain barrier leakage. Am. J. Physiol. Cell Physiol. 2007, 292:C1256-C1262.
20. Han B.H., Zhou M.L., Abousaleh F., Brendza R.P., Dietrich H.H., Koenigsknecht-Talboo J., Cirrito J.R., Milner E., Holtzman D.M., Zipfel G.J. Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: contribution of soluble and insoluble amyloid-beta peptide, partial restoration via gamma-secretase inhibition. J. Neurosci. 2008, 28:13542-13550.
21. Hanyu H., Sato T., Hirao K., Kanetaka H., Iwamoto T., Koizumi K. The progression of cognitive deterioration and regional cerebral blood flow patterns in Alzheimer's disease: a longitudinal SPECT study. J. Neurol. Sci. 2010, 290:96-101.
22. Maier F.C., Wehrl H.F., Schmid A.M., Mannheim J.G., Wiehr S., Lerdkrai C., Calaminus C., Stahlschmidt A., Ye L., Burnet M., et al. Longitudinal PET-MRI reveals β-amyloid deposition and rCBF dynamics and connects vascular amyloidosis to quantitative loss of perfusion. Nat. Med. 2014, 20:1485-1492.
23. Montagne A., Barnes S.R., Sweeney M.D., Halliday M.R., Sagare A.P., Zhao Z., Toga A.W., Jacobs R.E., Liu C.Y., Amezcua L., et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron 2015, 85:296-302.
24. Nicolakakis N., Hamel E. Neurovascular function in Alzheimer's disease patients and experimental models. J. Cereb. Blood Flow Metab. 2011, 31:1354-1370.
25. Phares T.W., Kean R.B., Mikheeva T., Hooper D.C. Regional differences in blood-brain barrier permeability changes and inflammation in the apathogenic clearance of virus from the central nervous system. J. Immunol. 2006, 176:7666-7675.
26. Schlageter N.L., Carson R.E., Rapoport S.I. Examination of blood-brain barrier permeability in dementia of the Alzheimer type with [68Ga]EDTA and positron emission tomography. J. Cereb. Blood Flow Metab. 1987, 7:1-8.
27. St-Amour I., Paré I., Alata W., Coulombe K., Ringuette-Goulet C., Drouin-Ouellet J., Vandal M., Soulet D., Bazin R., Calon F. Brain bioavailability of human intravenous immunoglobulin and its transport through the murine blood-brain barrier. J. Cereb. Blood Flow Metab. 2013, 33:1983-1992.
28. Takeda S., Sato N., Ikimura K., Nishino H., Rakugi H., Morishita R. Increased blood-brain barrier vulnerability to systemic inflammation in an Alzheimer disease mouse model. Neurobiol. Aging 2013, 34:2064-2070.
29. Terwel D., Lasrado R., Snauwaert J., Vandeweert E., Van Haesendonck C., Borghgraef P., Van Leuven F. Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice. J. Biol. Chem. 2005, 280:3963-3973.
30. Toledo J.B., Arnold S.E., Raible K., Brettschneider J., Xie S.X., Grossman M., Monsell S.E., Kukull W.A., Trojanowski J.Q. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain 2013, 136:2697-2706.
31. Yoshiyama Y., Higuchi M., Zhang B., Huang S.M., Iwata N., Saido T.C., Maeda J., Suhara T., Trojanowski J.Q., Lee V.M. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007, 53:337-351.
32. Yu Y.J., Watts R.J. Developing therapeutic antibodies for neurodegenerative disease. Neurotherapeutics 2013, 10:459-472.
33. Yu Y.J., Zhang Y., Kenrick M., Hoyte K., Luk W., Lu Y., Atwal J., Elliott J.M., Prabhu S., Watts R.J., Dennis M.S. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci. Transl. Med. 2011, 3:84ra44.
34. Zhang Y., Chen K., Sloan S.A., Bennett M.L., Scholze A.R., O'Keeffe S., Phatnani H.P., Guarnieri P., Caneda C., Ruderisch N., et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci. 2014, 34:11929-11947.